Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
Dimple Butani,1 Nidhi Gupta,2 Gaurav Jyani,1 Pankaj Bahuguna,1 Rakesh Kapoor,3 Shankar Prinja1 1Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India; 2Department of Radiation Oncology, Government Medical College and...
Main Authors: | Butani D, Gupta N, Jyani G, Bahuguna P, Kapoor R, Prinja S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-11-01
|
Series: | Breast Cancer: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/cost-effectiveness-of-tamoxifen-aromatase-inhibitor-and-switch-therapy-peer-reviewed-fulltext-article-BCTT |
Similar Items
-
Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
by: Inga Bekes, et al.
Published: (2023-08-01) -
Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
by: Hao Liao, et al.
Published: (2022-05-01) -
Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews
by: Adam Todd, et al.
Published: (2024-02-01) -
Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
by: Roberta Rosso, et al.
Published: (2023-01-01) -
Adverse effects of adjuvant endocrine therapy
by: E. I. Kovalenko, et al.
Published: (2018-07-01)